Kitsukawa Shin-ichi, Yamamoto Yutaka, Hosoda Satoru, Otsuru Norihiko, Matsumoto Taro, Matsumoto Tetsuo, Aizawa Taku, Noda Kenjiro, Ito Takaaki
The Department of Urology, Tokyo Medical University Hachioji Medical Center.
Hinyokika Kiyo. 2006 Mar;52(3):167-72.
The clinical usefulness of the nuclear matrix protein 22 (NMP22) Bladder Chek test as a novel urine marker in the detection of patients with bladder cancer was evaluated in comparison with the urinary NMP22 enzyme-linked immunosorbent assay (ELISA) and urinary cytology. A total of 40 patients with pathologically proven bladder cancer voided urine specimen before treatment. The urine samples were divided for NMP22 Bladder Chek test, NMP22 ELISA, and urinary cytology. In the 40 patients with bladder cancer, the overall positive rate was 62.5% for the NMP22 Bladder Chek test, 55% for the NMP22 ELISA test, and 27.5% for urine cytology. There was a significant difference between NMP22 Bladder Chek, NMP22 ELISA and cytology. The positive rate with the NMP22 Bladder Chek and NMP22 ELISA was higher in the patients with high grade and large-size (1 cm < or =) tumor. In 40 patients presenting with microhematuria without urothelial cancer, the false positive rate 12.5, 10, and 0% for NMP22 Bladder Chek, NMP22 ELISA, and urinary cytology. No significant difference was found with the test. In conclusion, the urine NMP22 Bladder Chek test provided a higher positive rate than the NMP22 ELISA test and urinary cytology. Therefore, the NMP22 Bladder Chek test may be clinically more useful as a tumor marker for the diagnosis of bladder cancer.
通过与尿核基质蛋白22（NMP22）酶联免疫吸附测定（ELISA）和尿细胞学检查相比较，评估了NMP22膀胱检测作为一种新型尿液标志物在膀胱癌患者检测中的临床实用性。共有40例经病理证实的膀胱癌患者在治疗前留取尿液标本。将尿液样本分别用于NMP22膀胱检测、NMP22 ELISA检测和尿细胞学检查。在40例膀胱癌患者中，NMP22膀胱检测的总体阳性率为62.5%，NMP22 ELISA检测为55%，尿细胞学检查为27.5%。NMP22膀胱检测、NMP22 ELISA检测和细胞学检查之间存在显著差异。NMP22膀胱检测和NMP22 ELISA检测在高级别和大尺寸（1 cm及以上）肿瘤患者中的阳性率更高。在40例表现为镜下血尿但无尿路上皮癌的患者中，NMP22膀胱检测、NMP22 ELISA检测和尿细胞学检查的假阳性率分别为12.5%、10%和0%。各检测方法之间未发现显著差异。总之，尿NMP22膀胱检测的阳性率高于NMP22 ELISA检测和尿细胞学检查。因此，NMP22膀胱检测作为膀胱癌诊断的肿瘤标志物在临床上可能更有用。
